Avanos Medical Stock Price, News & Analysis

Avanos (NYSE: AVNS) and Siemens Healthineers announced a strategic co-marketing agreement to integrate Avanos radiofrequency ablation (RFA) technologies with Siemens mobile C-arm imaging systems for outpatient and interventional pain management.

The collaboration targets ambulatory surgery centers, hospitals, and interventional pain practices in the U.S., focusing on joint education, sales training, and marketing to promote a combined workflow that aims to improve procedural accuracy, efficiency, and consistency in patient care.

Avanos Medical (NYSE: AVNS) announced that CEO Dave Pacitti will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026 at approximately 2:15 p.m. PST. A live webcast will be available on the company Investors website and the presentation will be archived there for later viewing.

Avanos Medical (NYSE: AVNS) reported Q3 2025 results on Nov 5, 2025: total net sales of $177.8 million (+4.3% YoY) and a net loss of $1.4 million (vs. income of $5.9M a year ago). Adjusted net income was $10.1 million and adjusted diluted EPS was $0.22. The company closed the acquisition of Nexus Medical and delivered double‑digit volume growth in its Specialty Nutrition Systems (SNS) segment. Management raised and narrowed full‑year 2025 guidance to $690–700 million revenue and adjusted diluted EPS of $0.85–0.95. The company recorded a $77.0 million goodwill impairment earlier in 2025 and had $70.5 million cash and $102.8 million net debt at Sept 30, 2025.

Avanos Medical (NYSE: AVNS) will webcast a conference call on Wed., Nov 5, 2025 at 9:00 AM ET to discuss third quarter 2025 financial results and business highlights. A news release with results will be issued before market open the same day. The call will be hosted by CEO Dave Pacitti and SVP & CFO Scott Galovan. Investors can register for instant phone access, dial 1-646-357-8785 or 1-800-836-8184, or join a simultaneous webcast via the Avanos Investors website. A replay will be available within two hours after the call and accessible for one week; dial-in replay numbers and passcode 21545# are provided. Avanos is a medical technology company focused on nutrition, opioid-reduction solutions, and post-surgical recovery devices.

WRS Group announced it will acquire substantially all assets and rights to Avanos Medical (NYSE: AVNS) US Game Ready® orthopedic rental business, with ownership transfer effective Dec. 1, 2025.

The transaction includes a long-term distribution and supply agreement: Avanos will continue to manufacture and supply Game Ready systems and accessories and provide transition support through the end of 2025 to ensure uninterrupted customer service.

WRS said the acquisition strengthens its US orthopedic recovery offerings and aims to expand access to clinically proven cold-and-compression therapies for patients, surgeons, and rehabilitation providers.

Avanos Medical (NYSE: AVNS) has announced the acquisition of Nexus Medical, a private medical device company known for its proprietary TKO® anti-reflux needleless connector technology. The technology is specifically designed for safer nutrition and medication delivery in high-acuity settings like NICUs and PICUs.

The strategic acquisition enhances Avanos' Specialty Nutrition Systems business, particularly strengthening its position in neonatal patient care. The TKO® technology features a patented pressure-activated tri-seal silicone valve that reduces blood reflux issues during IV-based treatments.

The transaction was financed with available cash and is expected to be immediately accretive to revenue growth and earnings per share.

Avanos Medical (NYSE:AVNS) has announced two significant leadership changes. Scott Galovan has been appointed as Senior Vice President and Chief Financial Officer, effective August 1, 2025. Galovan, who previously served as SVP of strategy and corporate development at Avanos, brings 12 years of company experience and a strong background in acquisitions and divestitures.

Additionally, CEO David Pacitti has been appointed to the company's Board of Directors, also effective August 1, 2025. In his CFO role, Galovan will oversee global finance, treasury, tax, corporate development, investor relations, accounting, and the Enterprise Program Management Office, reporting directly to Pacitti.

Avanos Medical (NYSE:AVNS) reported Q2 2025 financial results with total net sales of $175.0 million, up 1.9% year-over-year. The company posted a net loss of $76.8 million, compared to net income of $4.3 million in Q2 2024, primarily due to a $77.0 million goodwill impairment charge.

The Specialty Nutrition Systems segment showed strong performance with net sales of $102.7 million, while Pain Management & Recovery segment reached $61.0 million. The company announced the divestiture of its HA product line to Channel-Markers Medical and maintained its 2025 guidance of revenue between $665-685 million and adjusted EPS of $0.75-0.95.

Avanos Medical (NYSE:AVNS) has announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical (CMM), a private company in Raleigh, NC. The divested portfolio includes TriVisc® and GenVisc® 850 injection products for osteoarthritis knee pain treatment.

The strategic move aligns with Avanos' transformation strategy to focus on its core segments in Pain Management & Recovery and Specialty Nutrition Systems. The ownership transfer is effective immediately, with Avanos providing transition support through the end of 2025 to ensure continuity of service.